Dear reader of ADxS.org, please excuse the disruption.

ADxS.org needs around €58,500 in 2024. Unfortunately 99,8 % of our readers do not donate. If everyone reading this appeal made a small contribution, our fundraising campaign for 2024 would be over after a few days. This appeal is displayed 23,000 times a week, but only 75 people donate. If you find ADxS.org useful, please take a minute to support ADxS.org with your donation. Thank you very much!

Since 01.06.2021 ADxS.org is supported by the non-profit ADxS e.V. Donations to ADxS e.V. are tax-deductible in Germany (up to €300, the remittance slip is sufficient as a donation receipt).

If you would prefer to make an active contribution, you can find ideas for Participation or active support here.

$45213 of $63500 - as of 2024-10-31
71%
Header Image
Trazodone for ADHD

Sitemap

Trazodone for ADHD

Trazodone is an antidepressant (SARI) that is sometimes helpful as a sleep aid for ADHD.
More on this at Krause.1

  • Phenylpiperazine
  • Blockade of the 5HT2A receptors leads to an increase in dopamine in the striatum due to glutamate reduction and increases serotonergic neurotransmission via the 5-HT1A receptors
  • Low dose (up to 50 mg): 5HT2A receptor antagonist
  • Higher doses are also serotonergic and antihistaminergic. At low doses (up to 50 mg) it has no serotonergic effect.
  • Sleep-promoting in ADHD when taken in low doses (25 to 100 mg)
  • Half-life 5 to 9 hours
  • No impairment of sexual functions
  • No increase in body weight
  • Strongly inhibits α1 receptors
  • Weakly inhibits α2 and H1 receptors
  • Attenuating effect on tremor
  • Not contraindicated in glaucoma and prostate problems
  • No extrapyramidal effect (no motor restlessness)
  • No potentiation of adrenergic transmission
  • No anticholinergic activity, therefore does not have the typical side effects of tricyclic antidepressants
  • Cross effects:
    • Should not be combined with MAO inhibitors or (especially if high doses) with serotonergic medication
Diese Seite wurde am 21.03.2024 zuletzt aktualisiert.